Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PLYX
POLARYX THERAPEUTICS, INC. COMMON STOCK
NASDAQ
$2.07
▼ DOWN 3.27% (-0.07)

KEY STATISTICS

Market Cap$103.18 M
52w High$48.91
52w Low$1.86
Dividend Yield—
Frequency—
P/E-10.62
Volume108.47K
Shares Out.49.85M

COMPANY

LEADERSHIP

Alex Yang
CHIEF EXECUTIVE
Alex Yang

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 2, 2026
METHOD OF GOING PUBLIC
Direct Listing
FULL TIME EMPLOYEES
11

PRICE TARGET

Target High$7.00
Target Low$6.00
Target Median$6.50
Target Consensus$6.50

PRICE

$2.07 ▼ DOWN 3.27% (−$0.07)
$2.04$2.08$2.12$2.169:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM2.07

About Polaryx Therapeutics, Inc. Common Stock

https://polaryx.com ↗

Polaryx Therapeutics, founded in 2014 in Paramus, NJ, develops small molecule therapies for lysosomal storage and neurodegenerative disorders, including PLX-100, PLX-200, and PLX-300.

INDUSTRY

Biotechnology

A PRODUCT POLARYX THERAPEUTICS, INC. COMMON STOCK IS KNOWN FOR

PLX-200
PLX-200

PLX-200, Polaryx Therapeutics' lead oral small molecule for rare pediatric lysosomal storage disorders, is preparing for a Phase 2 trial (SOTERIA) in 2026, targeting unmet medical needs in rare diseases.

COMPETITORS

COMPETITOR
DNLI COMPARE
GANX COMPARE
RGNX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
11
LISTED HERE
1
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.5M

INSTITUTIONAL OWNERSHIP

SHARES OWNED
0.05%
HOLDERS
1
TOP 1 OF 1 · RANKED BY POSITION SIZE
Bank Of America Corp /De/
25.9K sh · $195.66K

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

SECTORS PEERS

PEERPRICE
JBIO$21.34COMPARE
CBIO$17.15COMPARE
FHTX$7.07COMPARE
LYEL$15.53COMPARE
ANTX$5.81COMPARE
KLRS$4.15COMPARE
PTHS$25.51COMPARE
NXTC$6.29COMPARE